Entrepreneurial Adolescence: US Genomics

“But as it became clear that personalized medicine, while a powerful vision, wasn’t going to revolutionize the healthcare system overnight, U.S. Genomics entered a wrenching transitional period. I call it entrepreneurial adolescence, which has the following symptoms: The investors get impatient, the founder is booted, a chief executive with more business experience parachutes in, other executives are shuffled, and the company starts searching for near-term revenue possibilities. All that is happening at U.S. Genomics.”

From this Boston Globe article by Scott Kirsner. The near-term revenue possibilities are no longer high throughput genome sequencing, as they once were.


Comments are closed.